KromaTiD secured $3.58 million to advance its next-generation cytogenetic tools for oncology and rare diseases, using molecular assays that detect complex genomic rearrangements and accelerate therapeutic discovery.
KromaTiD secured $3.58 million to advance its next-generation cytogenetic tools for oncology and rare diseases, using molecular assays that detect complex genomic rearrangements and accelerate therapeutic discovery.
